IL150710A0 - Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation - Google Patents

Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation

Info

Publication number
IL150710A0
IL150710A0 IL15071001A IL15071001A IL150710A0 IL 150710 A0 IL150710 A0 IL 150710A0 IL 15071001 A IL15071001 A IL 15071001A IL 15071001 A IL15071001 A IL 15071001A IL 150710 A0 IL150710 A0 IL 150710A0
Authority
IL
Israel
Prior art keywords
receptor antagonist
smoking cessation
cannabinoid receptor
preparing medicines
central cannabinoid
Prior art date
Application number
IL15071001A
Other languages
English (en)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of IL150710A0 publication Critical patent/IL150710A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15071001A 2000-02-09 2001-02-07 Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation IL150710A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (1)

Publication Number Publication Date
IL150710A0 true IL150710A0 (en) 2003-02-12

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15071001A IL150710A0 (en) 2000-02-09 2001-02-07 Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation

Country Status (32)

Country Link
US (2) US6930122B2 (pl)
EP (1) EP1257275B1 (pl)
JP (2) JP2003522145A (pl)
CN (1) CN1250220C (pl)
AR (1) AR028505A1 (pl)
AT (1) ATE292467T1 (pl)
AU (1) AU781827B2 (pl)
BG (2) BG110386A (pl)
BR (1) BR0108126A (pl)
CA (1) CA2397262C (pl)
CZ (1) CZ296685B6 (pl)
DE (1) DE60109903T2 (pl)
DK (1) DK1257275T3 (pl)
EE (1) EE04836B1 (pl)
ES (1) ES2240416T3 (pl)
FR (1) FR2804604B1 (pl)
HU (1) HU225328B1 (pl)
IL (1) IL150710A0 (pl)
IS (1) IS6450A (pl)
MX (1) MXPA02007766A (pl)
NO (1) NO324521B1 (pl)
NZ (1) NZ519924A (pl)
PL (1) PL201685B1 (pl)
PT (1) PT1257275E (pl)
RS (1) RS50404B (pl)
RU (1) RU2257207C2 (pl)
SI (1) SI1257275T1 (pl)
SK (1) SK284952B6 (pl)
TW (1) TWI243677B (pl)
UA (1) UA72783C2 (pl)
WO (1) WO2001058450A2 (pl)
ZA (1) ZA200205317B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
CA2457675A1 (en) 2001-08-13 2003-02-27 Honeywell International Inc. Providing current control over wafer borne semiconductor devices using trenches
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
AU2003225964B2 (en) 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
WO2003086288A2 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
AU2003257145B2 (en) 2002-08-02 2008-11-13 Merck Sharp & Dohme Corp. Substituted furo (2,3-b) pyridine derivatives
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
KR20050088194A (ko) 2002-12-19 2005-09-02 머크 앤드 캄파니 인코포레이티드 치환된 아미드
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2004287849A1 (en) * 2003-10-30 2005-05-19 Merck Sharp & Dohme Corp. Aralkyl amines as cannabinoid receptor modulators
CA2586011C (en) 2004-07-12 2011-07-19 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
MX2007006695A (es) 2004-12-03 2007-08-14 Schering Corp Piperazinas sustituidas como antagonistas de cb1.
BRPI0706623A2 (pt) * 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
WO2008046905A1 (en) * 2006-10-20 2008-04-24 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
CA2692268A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
UA72783C2 (en) 2005-04-15
FR2804604B1 (fr) 2005-05-27
HUP0300237A3 (en) 2003-09-29
TWI243677B (en) 2005-11-21
HU225328B1 (en) 2006-09-28
US20050187253A1 (en) 2005-08-25
RS50404B (sr) 2009-12-31
EP1257275B1 (fr) 2005-04-06
EP1257275A2 (fr) 2002-11-20
ZA200205317B (en) 2003-09-04
PL201685B1 (pl) 2009-04-30
RU2257207C2 (ru) 2005-07-27
RU2002118309A (ru) 2004-02-20
CN1250220C (zh) 2006-04-12
BR0108126A (pt) 2003-01-28
AU3562001A (en) 2001-08-20
PL358221A1 (pl) 2004-08-09
JP2010018622A (ja) 2010-01-28
NO20023765D0 (no) 2002-08-08
WO2001058450A3 (fr) 2002-04-25
JP2003522145A (ja) 2003-07-22
BG65856B1 (bg) 2010-03-31
NO324521B1 (no) 2007-11-12
WO2001058450A2 (fr) 2001-08-16
IS6450A (is) 2002-06-28
EE200200439A (et) 2003-12-15
AR028505A1 (es) 2003-05-14
HUP0300237A2 (hu) 2003-07-28
BG106946A (bg) 2003-05-30
HK1051140A1 (en) 2003-07-25
EE04836B1 (et) 2007-06-15
NZ519924A (en) 2005-01-28
FR2804604A1 (fr) 2001-08-10
ES2240416T3 (es) 2005-10-16
DE60109903D1 (de) 2005-05-12
AU781827B2 (en) 2005-06-16
MXPA02007766A (es) 2002-10-11
ATE292467T1 (de) 2005-04-15
CA2397262C (en) 2007-09-11
US20030087933A1 (en) 2003-05-08
CZ296685B6 (cs) 2006-05-17
DK1257275T3 (da) 2005-08-08
US6930122B2 (en) 2005-08-16
CA2397262A1 (en) 2001-08-16
BG110386A (en) 2009-09-30
YU59002A (sh) 2005-07-19
SI1257275T1 (en) 2005-10-31
NO20023765L (no) 2002-10-09
CZ20022698A3 (cs) 2002-11-13
PT1257275E (pt) 2005-07-29
SK284952B6 (sk) 2006-03-02
CN1406128A (zh) 2003-03-26
SK11292002A3 (sk) 2003-02-04
DE60109903T2 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
IL150710A0 (en) Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
AU7667300A (en) Use of central cannabinoid receptor antagonist for preparing medicines
PL365377A1 (pl) Pochodne amidów jako antagoniści receptora NMDA
HUP0301671A3 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
IL153645A0 (en) Carboxamide compounds and their use as antagonists of a human 11cby receptor
HUP0302044A3 (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
EP1224173A4 (en) PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS
ZA98691B (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
IL148593A0 (en) T2r, a novel family of taste receptors
PL357348A1 (pl) Postacie dawkowane o podwójnym uwalnianiu czasowym zawierające lek nasenny o krótkotrwałym działaniu lub jego sól
HUP0700039A2 (en) Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation
AU1845402A (en) Nmda receptor agonist pharmaceutical compositions
HUP0201937A3 (en) Substituted 1,5-dihydropyrrol-2-on derivatives, process for producing them and pharmaceutical compositions containing them having nmda receptor antagonist effect
PL353613A1 (en) Application of oestrogen agonist/antagonist in production of a drug
PL356990A1 (pl) Pochodne izoksazolokarboksyamidu
GB0207104D0 (en) Stable hydrate of a muscarinic receptor antagonist
HUP0302003A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
HUP0201300A3 (en) Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them
GB0011817D0 (en) Antagonists of integrin receptors
HUP0300694A3 (en) Indole derivatives as mcp-1 receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
HUP0300470A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
PL376866A1 (pl) Nowe antagonistyczne pochodne receptora witronektyny, sposób ich przygotowania, ich zastosowanie jako leków i kompozycje farmaceutyczne je zawierające
HUP0201709A2 (en) Ureidopiperidine derivatives as selective human nk3 receptor antagonists, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions
IL158312A (en) Use of pyridoindolone derivatives for preparing anticancer medicines

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees